Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance
Journal of Microbiology · 2026
DOI: 10.71150/jm.2510019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Microbiology, 2026. Verfasst von Soo-Bong Park und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, beta-Lactamases, Anti-Bacterial Agents, Bacteria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Institute of Ocean Science and Technology.
Abstract (Originalsprache)
β-Lactam antibiotics marked the beginning of an era of effective and safe treatment for bacterial infections and remain the most widely prescribed antibacterial agents today. However, the emergence of antibiotic-resistant bacteria threatens a return to the pre-antibiotic era. In particular, bacterial expression of β-lactamases inactivating β-lactam antibiotics presents a challenge in antimicrobial therapy. While inhibitors against β-lactamases have been developed to protect the therapeutic efficacy of β-lactam antibiotics, the clinical use of β-lactamase inhibitors is constrained due to their limited inhibition spectrum and the emergence of inhibitor-resistant β-lactamase variants. As an effort to tackle this issue, here we reviewed the structural and mechanistic features of β-lactamases and their FDA-approved inhibitors. Moreover, mutations in clinically isolated β-lactamases that confer resistance against their inhibitors are compiled. The comprehensive overview offered in this review aims to support and stimulate the design of next-generation β-lactamase inhibitors for combating β-lactamase-mediated antibiotic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Republic of Korea.
- Graduate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul 03760, Republic of Korea.
- R&D Division, TODD PHARM CO. LTD., Seoul 03760, Republic of Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
- Korea Institute of Ocean Science and Technology
Zitieren
APA
Park, S. B., Kim, M. Y., & Cha, S. S. (2026). Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance. Journal of Microbiology. https://doi.org/10.71150/jm.2510019
Vancouver
Park SB, Kim MY, Cha SS. Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance. Journal of Microbiology. 2026. doi:10.71150/jm.2510019
BibTeX
@article{Park2026,
author = {Park, Soo-Bong and Kim, Myeong-Yeon and Cha, Sun-Shin},
title = {Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance},
journal = {Journal of Microbiology},
year = {2026},
doi = {10.71150/jm.2510019}
}
EUVIMED